MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer
(Thomson Reuters ONE) -
Novartis International AG /
MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive
efficacy results at interim analysis in HR+/HER2- advanced breast cancer
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Independent Data Monitoring Committee recommends stopping the trial early as
it met the primary endpoint, significantly extending progression-free
survival (PFS) compared to letrozole alone, at pre-planned interim
analysis[1]
* LEE011 (ribociclib), a CDK4/6 inhibitor, in combination with letrozole,
showed clinically meaningful improvement in PFS in postmenopausal women who
had received no prior therapy for advanced breast cancer[1]
* Full results will be presented at an upcoming medical congress; Novartis
will initiate discussions with regulatory authorities worldwide
Basel, May 18, 2016 - Novartis announced today that the MONALEESA-2 independent
Data Monitoring Committee recommended stopping the trial early as results of a
pre-planned interim analysis showed the trial met the primary endpoint of
clinically meaningful improvement in PFS[1]. MONALEESA-2 is a pivotal Phase III
trial of LEE011 (ribociclib), a cyclin dependent kinase inhibitor (CDK4/6), in
combination with letrozole, compared to letrozole alone in postmenopausal women
who had received no prior therapy for their hormone receptor positive, human
epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast
cancer[1].
"We are excited that these results validate our belief that LEE011 in
combination with letrozole can be a beneficial treatment option for women
diagnosed with HR+/HER2- advanced breast cancer," said Alessandro Riva, Global
Head, Oncology Development and Medical Affairs, Novartis Oncology. "Novartis is
dedicated to continuing to discover and develop innovative targeted therapies
that help improve and extend the lives of women living with this disease."
As part of the company's ongoing commitment to addressing the needs of patients
living with advanced breast cancer, Novartis will be evaluating possible
expanded access programs in some regions to help ensure women who may benefit
from LEE011 have access to it.
The adverse events observed with LEE011 in combination with letrozole in
MONALEESA-2 were generally consistent with their respective known adverse event
profiles[1].
The MONALEESA-2 trial will continue to assess overall survival data. Detailed
efficacy and safety data will be submitted for presentation at a major medical
congress and Novartis will begin discussions with global health authorities
about regulatory filings.
About MONALEESA-2
MONALEESA-2 (Mammary ONcology Assessment of LEE011's Efficacy and SAfety-2) is a
Phase III randomized, double blind, placebo controlled, multicenter global
registration trial to evaluate the safety and efficacy of LEE011 in combination
with letrozole compared to letrozole alone in postmenopausal women with
HR+/HER2- advanced breast cancer who received no prior therapy for their
advanced breast cancer[1].
The trial was conducted at 294 clinical trial sites globally and randomized 668
patients in a 1:1 ratio stratified by the presence of liver and/or lung
metastases[1]. Patients received LEE011 600 mg/daily (three weeks on and one
week off), or placebo, in combination with letrozole 2.5 mg/daily per the
approved label[1].
The primary endpoint of the trial was PFS[1]. Secondary endpoints included:
overall survival, overall response rate, clinical benefit rate, health-related
quality of life, safety and tolerability[1].
About LEE011 (ribociclib)
LEE011 (ribociclib) is a cyclin dependent kinase inhibitor (CDKi), a new class
of drugs that help slow the progression of cancer by inhibiting two proteins
called cyclin dependent kinase 4 and 6 (CDK4/6). These proteins, when over-
activated in a cell, can enable cancer cells to grow and divide too quickly.
LEE011 has been studied in non-clinical models and is currently being evaluated
in combination with additional endocrine agents as part of the MONALEESA
clinical trial program. LEE011 is not approved for any indication in any market
at this time.
The MONALEESA-3 trial is evaluating LEE011 in combination with fulvestrant
compared to fulvestrant alone in men and post-menopausal women with HR+/HER2-
advanced breast cancer who have received no or a maximum of one prior endocrine
therapy. The MONALEESA-7 trial is investigating LEE011 in combination with
endocrine therapy and goserelin compared to endocrine therapy and goserelin
alone in pre-menopausal women with HR+/HER2- advanced breast cancer who have not
previously received endocrine therapy. Both Phase III programs, MONALEESA-3 and
MONALEESA-7 are recruiting patients worldwide.
LEE011 was developed by Novartis Institutes for BioMedical Research (NIBR) under
a research collaboration with Astex Pharmaceuticals.
About Novartis in advanced breast cancer
For more than 25 years, Novartis has been at the forefront of driving scientific
advancements for breast cancer patients and improving clinical practice in
partnership with the global community[1]. With one of the most diverse breast
cancer pipelines and the largest number of breast cancer compounds in
development, Novartis leads the industry in discovery of new therapies and
combinations, especially in HR+ advanced breast cancer, the most common form of
the disease[1].
About advanced breast cancer
Advanced breast cancer comprises metastatic breast cancer (stage IV) and locally
advanced breast cancer (stage III)[2]. Metastatic breast cancer is the most
serious form of the disease and occurs when the cancer has spread to other parts
of the body, such as the brain, bones or liver[2]. Locally advanced breast
cancer occurs when the cancer has spread to lymph nodes and/or other tissue in
the area of the breast, but not to distant sites in the body[2].
HR+/HER2- advanced breast cancer is the most common type of advanced breast
cancer, with an estimated 220,000 women diagnosed globally each year[3],[4]. HR+
advanced breast cancer is a group of cancers that express receptors for certain
hormones, such as estrogen and progesterone[5]. Cancer cell growth can be driven
by these hormones[5].
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by words such as "will," "pursue," "belief," "dedicated," "continuing,"
"commitment," "possible," "may," "to evaluate," "being evaluated," "is
evaluating," "is investigating," "are recruiting," or similar terms, or by
express or implied discussions regarding potential new indications or labeling
for LEE011, or regarding potential future revenues from LEE011. You should not
place undue reliance on these statements. Such forward-looking statements are
based on the current beliefs and expectations of management regarding future
events, and are subject to significant known and unknown risks and
uncertainties. Should one or more of these risks or uncertainties materialize,
or should underlying assumptions prove incorrect, actual results may vary
materially from those set forth in the forward-looking statements. There can be
no guarantee that LEE011 will be submitted or approved for any additional
indications or labeling in any market, or at any particular time. Nor can there
be any guarantee that LEE011 will be commercially successful in the future. In
particular, management's expectations regarding LEE011 could be affected by,
among other things, the uncertainties inherent in research and development,
including unexpected clinical trial results and additional analysis of existing
clinical data; unexpected regulatory actions or delays or government regulation
generally; the company's ability to obtain or maintain proprietary intellectual
property protection; general economic and industry conditions; competition in
general; global trends toward health care cost containment, including ongoing
pricing pressures; unexpected manufacturing, safety or quality issues, and other
risks and factors referred to in Novartis AG's current Form 20-F on file with
the US Securities and Exchange Commission. Novartis is providing the information
in this press release as of this date and does not undertake any obligation to
update any forward-looking statements contained in this press release as a
result of new information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care and cost-saving generic pharmaceuticals. Novartis is the only global
company with leading positions in these areas. In 2015, the Group achieved net
sales of USD 49.4 billion, while R&D throughout the Group amounted to
approximately USD 8.9 billion (USD 8.7 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 118,000
full-time-equivalent associates. Novartis products are available in more than
180 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
For Novartis multimedia content, please visit www.novartis.com/news/media-
library. For questions about the site or required registration, please contact:
media.relations(at)novartis.com
References
[1] Novartis Data on File.
[2] American Cancer Society. How do you determine the stage of breast cancer?
Available at http://www.cancer.org/cancer/breastcancer/detailedguide/breast-
cancer-staging. Accessed May 10, 2016.
[3] Dobrescu A, et al. Study of Estrogen Receptor and Progesterone Receptor
Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in
ER/PgR-Negative Invasive Breast Cancer. International Scholarly Research
Network. 2011;2011:1-5.
[4] Buckley N, et al. Breast Cancer. Decision Resources. March 2011:1-301.
[5] Redmond C. Breast Cancer Hormone Therapy Options. Available at
http://christineredmond.suite101.com/breast-cancer-hormone-therapy-options-
a197304. Accessed December 1, 2014.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Julie Masow
Novartis Global Media Relations Novartis Oncology Media Relations
+41 61 324 7999 (direct) +1 862 778 7220 (direct)
+41 79 593 4202 (mobile) +1 862 579 8456 (mobile)
eric.althoff(at)novartis.com julie.masow(at)novartis.com
e-mail: media.relations(at)novartis.com
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Richard Pulik +1 212 830 2448
Thomas Hungerbuehler +41 61 324 8425 Sloan Pavsner +1 212 830 2417
Isabella Zinck +41 61 324 7188
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/2013460/746190.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
[HUG#2013460]
Unternehmensinformation / Kurzprofil:
Datum: 18.05.2016 - 07:15 Uhr
Sprache: Deutsch
News-ID 471847
Anzahl Zeichen: 13426
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 339 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
